CHARLES MCDONOUGH: Open Payments
NPI 1619540705 · RICHMOND, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,544 in 133 payments from 21 companies in 2025. Trend: 2023 $1,536 · 2024 $1,563 · 2025 $2,544
Food & beverage: $2,544
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 20 | $461 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $364 |
| Vanda Pharmaceuticals Inc. | 17 | $326 |
| ABBVIE INC. | 21 | $288 |
| Alkermes, Inc. | 14 | $233 |
| Teva Pharmaceuticals USA, Inc. | 3 | $159 |
| Collegium Pharmaceutical, Inc. | 9 | $136 |
| Axsome Therapeutics, Inc. | 5 | $101 |
| Lundbeck LLC | 5 | $92 |
| E.R. Squibb & Sons, L.L.C. | 4 | $68 |
Products named: CAPLYTA, REXULTI, FANAPT, VRAYLAR, ARISTADA, ABILIFY ASIMTUFII, Jornay PM, UZEDY.
Industry payments across VA — which companies pay providers there.
